In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 4 Post-assessment*** Survey

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

2.What is your area of specialty?

Hematology

Oncology

Other (please specify)

3.How many years have you been in practice?

<1

1-10

11-20

>21

4.Please select the option that best describes your practice setting:

5.Of the patients you will see in the next month, about how many will benefit from the information you learned today?

6.After participating in this activity, how confident are you in the management of patients with ALL in your practice?

7.In the 3 clinical trials reviewed (SWOG 1318, EWALL-INO and INITIAL-1), which of the following outcomes were observed in elderly patients with Ph-ALL?(Required.)

Low rate of secondary malignancies

Low rate of late relapses

Low rate of induction deaths

Low rate of complete response

8.Which of the following interventions was evaluated in attempt to improve both the efficacy and tolerability of therapy in the SWOG1318 study in elderly patients with Ph-ALL?(Required.)

Omission of chemotherapy in induction and consolidation

Omission of maintenance chemotherapy

Dose reduction of chemotherapy in induction and consolidation

Dose reduction of blinatumomab by 50%

Evaluation Form
In order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety.

9.How committed are you to making changes in your practice based on your participation in this activity?(Required.)

If not committed or do not plan to make changes, please indicate reason

10.Which of the following best describes the impact of this activity on your performance?(Required.)

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

11.Which new strategies/skills/information will you apply to your area of practice?

Recognize the role of inotuzumab ozogamicin in the treatment of newly diagnosed CD22+, Ph-neg ALL based on the EWALL-INO study

Identify the utility of inotuzumab ozogamicin in the treatment of patients aged 56 years and older with ALL based on the INITIAL-1 study

Position blinatumomab as monotherapy followed by POMP maintenance in older adults with Ph-, B-cell ALL based on SWOG 1318 study

12.What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

13.After participating in today’s activity, I am now better able to:(Required.)

Strongly agree

Agree

Neutral

Disagree

Strongly disagree

Review recently presented clinical trial data in older adults with treatment-naïve, Philadelphia chromosome negative, acute lymphoblastic leukemia

Strongly agree

Agree

Neutral

Disagree

Strongly disagree

16.If you indicated that you perceived commercial bias or influence, please describe:

17.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

18.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

19.Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

First & Last Name

Degree/Credentials

ZIP/Postal Code

Country

Email Address

20.I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

No